<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548014" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548014/" /><meta name="ncbi_pagename" content="Ustekinumab - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ustekinumab - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Ustekinumab" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/04/20" /><meta name="citation_pmid" content="31643346" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548014/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ustekinumab" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/04/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548014/" /><meta name="description" content="Ustekinumab is a human monoclonal antibody to a polypeptide found on interleukin-12 and -23 that is used to treat autoimmune conditions and is approved for use in severe psoriasis. Ustekinumab is associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of idiosyncratic, clinically apparent liver injury. Ustekinumab has immunomodulatory activity and may cause reactivation of hepatitis B in susceptible patients." /><meta name="og:title" content="Ustekinumab" /><meta name="og:type" content="book" /><meta name="og:description" content="Ustekinumab is a human monoclonal antibody to a polypeptide found on interleukin-12 and -23 that is used to treat autoimmune conditions and is approved for use in severe psoriasis. Ustekinumab is associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of idiosyncratic, clinically apparent liver injury. Ustekinumab has immunomodulatory activity and may cause reactivation of hepatitis B in susceptible patients." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548014/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Ustekinumab/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548014/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D92EC04691D81000000000137005E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548014_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548014_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/UsnicAcid/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/UvaUrsi/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548014_"><span class="title" itemprop="name">Ustekinumab</span></h1><p class="small">Last Update: <span itemprop="dateModified">April 20, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Ustekinumab.OVERVIEW"><h2 id="_Ustekinumab_OVERVIEW_">OVERVIEW</h2><div id="Ustekinumab.Introduction"><h3>Introduction</h3><p>Ustekinumab is a human monoclonal antibody to a polypeptide found on interleukin-12 and -23 that is used to treat autoimmune conditions and is approved for use in severe psoriasis. Ustekinumab is associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of idiosyncratic, clinically apparent liver injury. Ustekinumab has immunomodulatory activity and may cause reactivation of hepatitis B in susceptible patients.</p></div><div id="Ustekinumab.Background"><h3>Background</h3><p>Ustekinumab (us&#x0201d; te kin&#x02019; ue mab) is a human monoclonal immunoglobulin G1 antibody to the p40 subunit polypeptide of both interleukin (IL)-12 and -23, cytokines that are important mediators of autoimmune reactions. IL-12 and IL-23 are found in the skin lesions of psoriasis and in the affected gastrointestinal mucosa of patients with inflammatory bowel disease. Ustekinumab was approved for use in psoriasis United States in 2010, and indications were subsequently expanded to include inflammatory bowel disease. Current indications include moderate-to-severe plaque psoriasis and active psoriatic arthritis, Crohn disease and ulcerative colitis. Ustekinumab has been evaluated in other autoimmune diseases including Crohn disease, but does not have official approval for use in other conditions. Ustekinumab is available in liquid solution in single use vials and prefilled syringes of 45 and 90 mg (90 mg/mL) under the brand name Stelara. The initial and maintenance dose and dose regimen varies by indication and body weight. After an initial loading doses, ustekinumab is typically given subcutaneously every 8 to 12 weeks. Side effects are usually mild, and may include infusion reactions, chills, fever, skin rash, fatigue, leukopenia and infections. Less common, but potentially severe side effects include serious infections, reactivation of tuberculosis, increased risk of malignancies and reversible posterior leukoencephalopathy syndrome (RPLS).</p></div><div id="Ustekinumab.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Mild-to-moderate serum aminotransferase elevations were reported to occur in 0.5% to 1.4% of patients during ustekinumab therapy. The elevations, however, were self-limited and resolved even with continuing cyclic therapy and were no more frequent than occurred with placebo. Neither during premarketing evaluation nor subsequently have there been case reports of clinically apparent, acute liver injury with symptoms or jaundice linked to ustekinumab therapy, but experience with its use has been limited.</p><p>Ustekinumab has immunosuppressive activity and it has been linked to rare instances of reactivation of hepatitis B. HBV reactivation typically occurs in patients with preexisting HBsAg and relatively inactive disease. Reactivation causes acute hepatocellular injury that can be severe and lead to acute liver failure and death or need for emergency liver transplantation. Cases of reactivation attributed to ustekinumab, however, have generally been mild, self-limited and not associated with symptoms or even <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations. Screening for hepatitis B before starting ustekinumab is not recommended in the product label, but screening has been considered to be &#x0201c;advisable&#x0201d; by academic societies in published guidelines on psoriasis therapy. Ustekinumab has not been linked convincingly to worsening of chronic hepatitis C in patients with psoriasis or to hepatic decompensation in patients with pre-existing cirrhosis. For these reasons, chronic liver disease and concurrent HCV infection are not considered contraindications to therapy.</p><p>Likelihood score: E* (unproven but suspected rare cause of clinically apparent liver injury, possibly reactivation of hepatitis B).</p></div><div id="Ustekinumab.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of liver injury in reactivation of hepatitis B appears to be a brisk immunological response to newly expressed viral antigens. Injury generally arises between courses of immunosuppressive therapy, which for ustekinumab is given every 8 or 12 weeks after induction (at 0 and 4 weeks).</p></div><div id="Ustekinumab.Outcome_and_Management"><h3>Outcome and Management</h3><p>Ustekinumab is a rare cause of liver injury, but has been linked to occasional cases of reactivation of hepatitis B. The product label for ustekinumab does not recommend routine screening for hepatitis B before initiation of therapy. However, guidelines for management of patients who are to receive ustekinumab prepared by some academic societies have recommended routine screening before starting treatment. Screening should include tests for HBsAg and anti-HBc (and perhaps also anti-HBs as this may help in management). Prophylaxis with a potent oral, antiviral agent effective against hepatitis B is recommended for persons who have HBsAg in serum. An alternative approach, which is perhaps more appropriate for ustekinumab and particularly for patients with anti-HBc without HBsAg in serum, is careful monitoring for HBV DNA during therapy and early institution of antiviral therapy if levels rise.</p><p>Drug Class: Dermatological Agents, <a href="/books/n/livertox/PsoriasisDrugs/">Psoriasis Agents</a>; <a href="/books/n/livertox/AntirheumaticAgents/">Antirheumatic Agents</a>; <a href="/books/n/livertox/MonoclonalAntibodies/">Monoclonal Antibodies</a></p></div></div><div id="Ustekinumab.PRODUCT_INFORMATION"><h2 id="_Ustekinumab_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Ustekinumab &#x02013; Stelara&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Dermatological Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c77a9664-e3bb-4023-b400-127aa53bca2b" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Ustekinumab.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Ustekinumab_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Ustekinumab.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548014/table/Ustekinumab.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ustekinumab.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Ustekinumab.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Ustekinumab.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Ustekinumab.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Ustekinumab.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Ustekinumab.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ustekinumab</td><td headers="hd_h_Ustekinumab.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135302166" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">815610-63-0</a></td><td headers="hd_h_Ustekinumab.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_Ustekinumab.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></div><div id="Ustekinumab.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Ustekinumab_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 April 2020</p><p>Abbreviations: TNF, tumor necrosis factor; HER-2, human epidermal growth factor receptor 2; IL-17, interleukin 17.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Ustekinumab.REF.reuben.2011">Reuben A. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 569-91.<div><i>(Review of hepatotoxicity of immunosuppressive agents; does not mention ustekinumab specifically, but discusses the problems of reactivation of hepatitis B and states that "the biological immunosuppressants are largely free from hepatotoxicity, with the exception of the tumor necrosis factor [TNF] alpha antagonists").</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.krensky.2018">Krensky AM, Azzi JR, Hafler DA. Immunosuppressants and tolerogens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-53.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.leonardi.2008.1665">Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, et al.  PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <span><span class="ref-journal">Lancet. </span>2008;<span class="ref-vol">371</span>(9625):1665–74.</span> [<a href="/pubmed/18486739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18486739</span></a>]<div><i>(Among 766 patients with psoriasis treated with 1 of 2 doses of ustekinumab or placebo for 12 weeks, response rates were 67% and 66% with ustekinumab vs 3% with placebo, and side effects were similar and "results of laboratory results were much the same" in the 3 groups).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.papp.2008.1675">Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, et al.  PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). <span><span class="ref-journal">Lancet. </span>2008;<span class="ref-vol">371</span>(9625):1675–84.</span> [<a href="/pubmed/18486740" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18486740</span></a>]<div><i>(Among 1230 patients with psoriasis treated for 12 weeks with 1 of 2 doses of ustekinumab or placebo, clinical response rates were 67% and 76% with ustekinumab vs 4% with placebo, and "rates of laboratory abnormalities were similar between groups, and no differences were noted in liver aminotransferase concentrations").</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.gottlieb.2009.633">Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. <span><span class="ref-journal">Lancet. </span>2009;<span class="ref-vol">373</span>(9664):633–40.</span> [<a href="/pubmed/19217154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19217154</span></a>]<div><i>(Among 146 patients with psoriatic arthritis treated with either ustekinumab or placebo, responses at week 12 were more frequent with ustekinumab [42% vs 10%] and, while overall rates of adverse events were similar [61% vs 63%], ALT elevations occurred in 4% of ustekinumab vs 1% of placebo recipients).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.griffiths.2010.118">Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, et al. ACCEPT Study Group.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">362</span>:118–28.</span> [<a href="/pubmed/20071701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20071701</span></a>]<div><i>(Among 903 patients with psoriasis treated with 1 of 2 doses of ustekinumab vs etanercept for 12 weeks, clinical response rates were higher with ustekinumab [68-74% vs 57%], while rates of ALT elevations were similar [0.5-0.9% vs 1.2%]).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF7">Ustekinumab (Stelara) for psoriasis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2010;<span class="ref-vol">52</span>(1330):7–8.</span> [<a href="/pubmed/20208473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20208473</span></a>]<div><i>(Concise summary of mechanism of action, efficacy, safety and costs of ustekinumab in patients with psoriasis, mentions possibility of reactivation of tuberculosis, but not reactivation of hepatitis B, ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.tsai.2011.154">Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, Li S, et al.  PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). <span><span class="ref-journal">J Dermatol Sci. </span>2011;<span class="ref-vol">63</span>:154–63.</span> [<a href="/pubmed/21741220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21741220</span></a>]<div><i>(Among 121 patients with psoriasis treated with ustekinumab or placebo for 12 weeks, response rates with greater with ustekinumab [67% vs 5%], while "abnormal hepatic function" was less [0% vs 3.3%], although with long term ustekinumab therapy enzyme elevations were more common [7.3-8.5%], most abnormalities however being attributed to concurrent isoniazid therapy).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.oketani.2011.65">Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: A perspective from Japan. <span><span class="ref-journal">J Gastroenterol Hepatol. </span>2011;<span class="ref-vol">26</span> Suppl 1:65–71.</span> [<a href="/pubmed/21199516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21199516</span></a>]<div><i>(Analysis of from multicenter study in Japan lists reactivation of HBV as an increasing cause of acute liver failure).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.mastroianni.2011.3881">Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, et al.  Current trends in management of hepatitis B virus reactivation in the biologic therapy era. <span><span class="ref-journal">World J Gastroenterol. </span>2011;<span class="ref-vol">17</span>:3881–7.</span> [<a href="/pmc/articles/PMC3198017/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3198017</span></a>] [<a href="/pubmed/22025876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22025876</span></a>]<div><i>(Review of the cause and risk factors for reactivation of HBV and the role of preventive strategies).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.opel.2012.1498">Opel D, Economidi A, Chan D, Wasfi Y, Mistry S, Vergou T, Antoniou C, Sofen H. Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab. <span><span class="ref-journal">J Drugs Dermatol. </span>2012;<span class="ref-vol">11</span>:1498–501.</span> [<a href="/pubmed/23377523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23377523</span></a>]<div><i>(Two men, 33 and 40 years old, with severe psoriasis developed acute hepatitis B during ustekinumab therapy and recovered with clearance of HBsAg).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.lebwohl.2012.731">Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, et al.  Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <span><span class="ref-journal">J Am Acad Dermatol. </span>2012;<span class="ref-vol">66</span>:731–41.</span> [<a href="/pubmed/21930328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21930328</span></a>]<div><i>(Analysis of aggregate safety data from 3219 patients in 4 controlled trials of ustekinumab in psoriasis with variable extension periods reported "no notable differences in routine laboratory parameters were observed between patients treated with ustekinumab or placebo").</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.gordon.2012.742">Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, et al.  Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. <span><span class="ref-journal">J Am Acad Dermatol. </span>2012;<span class="ref-vol">66</span>:742–51.</span> [<a href="/pubmed/21978572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21978572</span></a>]<div><i>(Analysis of aggregate safety data from 4 controlled trials of ustekinumab with extension for up to 3 years demonstrated no increase in rates of serious and opportunistic infections or malignancy; no analysis of ALT elevations or mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.sandborn.2012.1519">Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, et al. CERTIFI Study Group.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">367</span>:1519–28.</span> [<a href="/pubmed/23075178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23075178</span></a>]<div><i>(Among 526 patients with Crohn disease treated with 1 of 3 doses of ustekinumab or placebo for 16 weeks, response rates were higher with ustekinumab [34-40% vs 24%] and rates of adverse events were similar; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.chiu.2013.1295">Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. <span><span class="ref-journal">Br J Dermatol. </span>2013;<span class="ref-vol">169</span>:1295–303.</span> [<a href="/pubmed/23746170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23746170</span></a>]<div><i>(Among 18 patients with psoriasis and concurrent hepatitis B or C treated with ustekinumab, reactivation of HBV occurred in 2 of 11 with HBsAg, but with a rise in HBV DNA levels only, without symptoms or ALT elevations, while reactivation of HCV occurred in 1 of 4 patients marked by a rise in HCV RNA without change in ALT).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.abuchar.2013.381">Abuchar A, Vitiello M, Kerdel FA. Psoriasis treated with ustekinumab in a patient with hepatitis C. <span><span class="ref-journal">Int J Dermatol. </span>2013;<span class="ref-vol">52</span>:381–2.</span> [<a href="/pubmed/23414168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23414168</span></a>]<div><i>(62 year old man with psoriatic arthritis and chronic hepatitis C was treated with ustekinumab after intolerance or failure of other therapies and had no change in serum HCV RNA or ALT levels during the first few months of therapy).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.mcinnes.2013.780">McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, et al.  PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <span><span class="ref-journal">Lancet. </span>2013;<span class="ref-vol">382</span>(9894):780–9.</span> [<a href="/pubmed/23769296" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23769296</span></a>]<div><i>(Among 615 patients with psoriatic arthritis treated with 1 of 2 doses of ustekinumab or placebo, response rates at 12 weeks were greater with ustekinumab [42-49% vs 23%], while rates of adverse events were similar).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.zhu.2013.166">Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, Wang B. LOTUS Investigators. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). <span><span class="ref-journal">J Drugs Dermatol. </span>2013;<span class="ref-vol">12</span>:166–74.</span> [<a href="/pubmed/23377389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23377389</span></a>]<div><i>(Among 322 Chinese patients with psoriasis treated with 2 injections of ustekinumab or placebo, responses at week 12 were 83% with ustekinumab vs 11% with placebo, while ALT elevations occurred in only 1 patient in each group (&#x0003c;1%) and resolved spontaneously).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.papp.2013.844">Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, et al.  PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <span><span class="ref-journal">Br J Dermatol. </span>2013;<span class="ref-vol">168</span>:844–54.</span> [<a href="/pubmed/23301632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23301632</span></a>]<div><i>(Pooled analysis of 4 controlled trials of ustekinumab for psoriasis in 3117 patients found no excess in serious adverse events with long term ustekinumab therapy).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.navarro.2013.609">Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, et al.  Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. <span><span class="ref-journal">Br J Dermatol. </span>2013;<span class="ref-vol">168</span>:609–16.</span> [<a href="/pubmed/22985451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22985451</span></a>]<div><i>(A retrospective analysis identified 3 patients with psoriasis and chronic hepatitis C and 3 with chronic hepatitis B who were treated with ustekinumab, none of whom had a significant change in ALT or viral levels during treatment).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.meng.2014.696">Meng Y, Dongmei L, Yanbin P, Jinju F, Meile T, Binzhu L, Xiao H, et al.  Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. <span><span class="ref-journal">Clin Exp Dermatol. </span>2014;<span class="ref-vol">39</span>:696–707.</span> [<a href="/pubmed/25039593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25039593</span></a>]<div><i>(Systematic review of 9 controlled trials of ustekinumab which included 11,381 patients mentions that the rate of adverse events [including serious infections] with treatment was similar to that in placebo controls; no mention of ALT elevations, hepatotoxicity or reactivation of hepatitis B).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.tamori.2014.1715">Tamori A, Hino M, Kawamura E, Fujii H, Uchida-Kobayashi S, Morikawa H, Nakamae H, et al.  A prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. <span><span class="ref-journal">J Gastroenterol Hepatol. </span>2014;<span class="ref-vol">29</span>:1715–21.</span> [<a href="/pubmed/24730465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24730465</span></a>]<div><i>(Among patients with anti-HBc without HBsAg not receiving prophylaxis, reactivation of HBV occurred in 26% of 19 patients undergoing HCT [onset at 9-36 months] and 10% of 30 patients given rituximab based chemotherapy [onset after 2-10 months], all of whom had anti-HBs titers below 200 mIU/mL before therapy and all of whom were successfully treated with entecavir).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.ritchlin.2014.990">Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, et al.  PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. <span><span class="ref-journal">Ann Rheum Dis. </span>2014;<span class="ref-vol">73</span>:990–9.</span> [<a href="/pmc/articles/PMC4033144/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4033144</span></a>] [<a href="/pubmed/24482301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24482301</span></a>]<div><i>(Among 312 patients with psoriatic arthritis in a 24 week controlled trial, clinical responses occurred in 44% of ustekinumab vs 20% of placebo recipients, and rates of side effects were similar without ustekinumab related severe adverse events or tuberculosis; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF24">Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2014;<span class="ref-vol">56</span>(1435):10–2.</span> [<a href="/pubmed/24662976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24662976</span></a>]<div><i>(Concise review of the mechanisms of action, clinical efficacy, safety and cost of ustekinumab and certolizumab shortly after their approval for use in psoriatic arthritis; no mention of hepatotoxicity or reactivation of hepatitis B).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.motaparthi.2014.178">Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S., Medical Board of the National Psoriasis Foundation.  From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. <span><span class="ref-journal">J Am Acad Dermatol. </span>2014;<span class="ref-vol">70</span>:178–86.</span> [<a href="/pubmed/24220724" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24220724</span></a>]<div><i>(Mentions that little is known about the effects of ustekinumab on HBV infection, but that screening for hepatitis B markers is "advisable" before its use).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.steglich.2014.652">Steglich RB, Meneghello LP, Carvalho AV, Cheinquer H, Muller FM, Reginatto FP. The use of ustekinumab in a patient with severe psoriasis and positive HBV serology. <span><span class="ref-journal">An Bras Dermatol. </span>2014;<span class="ref-vol">89</span>:652–4.</span> [<a href="/pmc/articles/PMC4148283/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4148283</span></a>] [<a href="/pubmed/25054756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25054756</span></a>]<div><i>(53 year old man with psoriasis and anti-HBc without HBsAg in serum was given lamivudine prophylaxis and treated with ustekinumab for 3 years with an excellent response and no evidence of reactivation of hepatitis B).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.llamasvelasco.2015.470">Llamas-Velasco M, Concha-Garz&#x000f3;n MJ, Garc&#x000ed;a-Diez A, Daud&#x000e9;n E. Liver injury in psoriasis patients receiving ustekinumab: a retrospective study of 44 patients treated in the clinical practice setting. <span><span class="ref-journal">Actas Dermosifiliogr. </span>2015;<span class="ref-vol">106</span>:470–6.</span> [<a href="/pubmed/25912374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25912374</span></a>]<div><i>(Among 44 patients with psoriasis treated with ustekinumab for 1 to 5 years, 6 developed minor ALT elevations on therapy [peak values 39 to 74 U/L], but all resolved without jaundice and without dose modifications).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, only four cases were attributed to a monoclonal antibody [3 to infliximab and 1 to adalimumab; no cases were attributed to ustekinumab).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.sanzbueno.2015.477">Sanz-Bueno J, Vanaclocha F, Garc&#x000ed;a-Doval I, Torrado R, Carretero G, Daud&#x000e9;n E, Patricia Ruiz-Genao D, et al.  members of the BIOBADADERM group. Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database. <span><span class="ref-journal">Actas Dermosifiliogr. </span>2015;<span class="ref-vol">106</span>:477–82.</span> [<a href="/pubmed/25776200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25776200</span></a>]<div><i>(Among 20 patients with psoriasis who had anti-HBc without HBsAg in serum and were treated with biologic agents, none developed evidence of reactivation of hepatitis B including 6 who received ustekinumab for an average of 18 months).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.hirschfield.2016.189">Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, Johanns J, et al. PURIFI Study Group.  Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <span><span class="ref-journal">Hepatology. </span>2016;<span class="ref-vol">64</span>:189–99.</span> [<a href="/pubmed/26597786" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26597786</span></a>]<div><i>(Among 20 patients with primary biliary cirrhosis treated with ustekinumab for up to 28 weeks, drop outs were frequent and serum alkaline phosphatase, ALT and AST improved minimally [9%-11%], no patients achieving criteria for a response, but also no patients developing worsening of blood test results; one subject had a variceal hemorrhage).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.snast.2017.88">Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. <span><span class="ref-journal">J Am Acad Dermatol. </span>2017;<span class="ref-vol">77</span>:88–97.e5.</span> [<a href="/pubmed/28495497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28495497</span></a>]<div><i>(Among 25 patients with psoriasis and anti-HBc without HBsAg in serum who were treated with biologic agents, including 9 treated with ustekinumab, none developed serum ALT elevations or evidence of HBV reactivation).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.lovero.2018.221">Lovero R, Losurdo G, Mastromauro M, Castellaneta NM, Mongelli A, Gentile A, Di Leo A, et al.  A case of severe transaminase elevation following a single ustekinumab dose with remission after drug withdrawal. <span><span class="ref-journal">Curr Drug Saf. </span>2018;<span class="ref-vol">13</span>:221–3.</span> [<a href="/pubmed/30027852" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30027852</span></a>]<div><i>(61 year old woman with psoriasis developed marked ALT elevations after a single, initial injection of ustekinumab [ALT 1212 U/L] and recovered but was not retreated).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.ting.2018.873">Ting SW, Chen YC, Huang YH. Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab. <span><span class="ref-journal">Clin Drug Investig. </span>2018;<span class="ref-vol">38</span>:873–80.</span> [<a href="/pubmed/29968197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29968197</span></a>]<div><i>(Among 93 patients with psoriasis treated with ustekinumab, 10 with HBsAg [2 given prophylaxis], 24 with anti-HBc without HBsAg, and 59 with no HBV markers [n=59], 2 with HBsAg, 1 with anti-HBc and none without markers developed reactivation of HBV during therapy, but all cases were asymptomatic with only minor and transient elevations in HBV DNA).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.begon.2018.512">Begon E, Beneton N, Poiraud C, Droitcourt C, Jacobzone C, Vermersch-Langlin A, Descamps V, et al.  Groupe d'Etudes Multicentrique GEM RESOPSO. Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases. <span><span class="ref-journal">Br J Dermatol. </span>2018;<span class="ref-vol">179</span>:512–3.</span> [<a href="/pubmed/29480522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29480522</span></a>]<div><i>(Among 23 patients with alcoholic cirrhosis and psoriasis who were treated with biologic agents [10 with ustekinumab], therapy was often effective and was well tolerated and although 5 developed infections, all were able to continue or resume therapy).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.almutairi.2018.553">AlMutairi N, Abouzaid HA. Safety of biologic agents for psoriasis in patients with viral hepatitis. <span><span class="ref-journal">J Dermatolog Treat. </span>2018;<span class="ref-vol">29</span>:553–6.</span> [<a href="/pubmed/29345515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29345515</span></a>]<div><i>(Among 39 patients with psoriasis and chronic viral hepatitis treated with biologic agents for at least 24 months, all were monitored but none developed clinical, biochemical or virologic evidence of reactivation [4 with HBsAg were given prophylaxis; 28 with anti-HBc without HBsAg and 7 with chronic hepatitis C]).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF.piaserico.2019.829">Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations. <span><span class="ref-journal">Am J Clin Dermatol. </span>2019;<span class="ref-vol">20</span>:829–45.</span> [<a href="/pubmed/31222626" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31222626</span></a>]<div><i>(Review of the risks of reactivation of hepatitis B from biologic agents used to treat psoriasis mentions that ustekinumab has a moderate risk and recommends monitoring of HBV DNA levels during therapy if prophylaxis with antiviral agents is not used).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF37">Drugs for psoriatic arthritis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2019;<span class="ref-vol">61</span>(1588):203–10.</span> [<a href="/pubmed/31999665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31999665</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety and costs of drugs for psoriatic arthritis mentions that common adverse events from secukinumab include injection site reactions, respiratory and candida infections, nausea and diarrhea ad uncommon but severe adverse events include tuberculosis, Crohn disease and hypersensitivity reactions).</i></div></div></li><li><div class="bk_ref" id="Ustekinumab.REF38">Drugs for psoriasis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2019;<span class="ref-vol">61</span>(1574):89–96.</span> [<a href="/pubmed/31381544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31381544</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety and costs of drugs for psoriasis mentions three IL-17A antagonists &#x02013; secukinumab, ixekizumab and brodalumab &#x02013; all of which are highly effective and relatively well tolerated; no mention of ALT elevations or hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548014</span><span class="label">PMID: <a href="/pubmed/31643346" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643346</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/UsnicAcid/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/UvaUrsi/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548014&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548014/?report=reader">PubReader</a></li><li><a href="/books/NBK548014/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548014" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548014" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Ustekinumab. [Updated 2020 Apr 20].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548014/pdf/Bookshelf_NBK548014.pdf">PDF version of this page</a> (114K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Ustekinumab+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Ustekinumab: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Ustekinumab" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Ustekinumab: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4868164" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4868164" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4868164" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29968197" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.</a><span class="source">[Clin Drug Investig. 2018]</span><div class="brieflinkpop offscreen_noflow">Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ting SW, Chen YC, Huang YH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Drug Investig. 2018 Sep; 38(9):873-880. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23746170" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.</a><span class="source">[Br J Dermatol. 2013]</span><div class="brieflinkpop offscreen_noflow">The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Br J Dermatol. 2013 Dec; 169(6):1295-303. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25054756" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The use of ustekinumab in a patient with severe psoriasis and positive HBV serology.</a><span class="source">[An Bras Dermatol. 2014]</span><div class="brieflinkpop offscreen_noflow">The use of ustekinumab in a patient with severe psoriasis and positive HBV serology.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Steglich RB, Meneghello LP, Carvalho AV, Cheinquer H, Muller FM, Reginatto FP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">An Bras Dermatol. 2014 Jul-Aug; 89(4):652-4. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643442" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Golimumab</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Golimumab<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20635831" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.</a><span class="source">[J Manag Care Pharm. 2010]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schafer JA, Kjesbo NK, Gleason PP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Manag Care Pharm. 2010 Jul-Aug; 16(6):402-16. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643346" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643346" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60469706ce712d3c9cad3808">Ustekinumab - LiverTox</a><div class="ralinkpop offscreen_noflow">Ustekinumab - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:28:38-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D92EC04691D81000000000137005E&amp;ncbi_session=CE8D92EC04697051_0311SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548014%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548014&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548014/&amp;ncbi_pagename=Ustekinumab - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D92EC04697051_0311SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>